Pacific Biosciences of California (PACB) Outperforms Expectations

Pacific Biosciences of California (PACB) closed at $1.50, up 1.35% from the previous session, outpacing the S&P 500. The stock has risen 27.59% in the past month, leading the Medical sector. Analysts expect earnings of -$0.18 per share and revenue of $36.46 million for the upcoming report.

Investors should note changes in analyst estimates for PACB, as they impact stock performance. The Zacks Rank system, currently rating PACB as a Strong Buy, has historically outperformed. The Medical – Instruments industry, where PACB belongs, has a Zacks Industry Rank of 173, in the bottom 30% of all industries.

Looking for breakout stocks? Only 220 Zacks Rank #1 Strong Buys exist at any given time, outperforming the S&P 500. Explore 7 compelling companies likely to surge in the Special Report, “7 Best Stocks for the Next 30 Days.” Be sure to monitor stock metrics on Zacks.com for strategic investment decisions.

Read more at Nasdaq: Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know